Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P43 vs Stelara in Moderate to Severe Plaque Psoriasis
NCT04673786Phase 3Completed
- Sponsor
- Celltrion
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ustekinumab CT-P43 in plaque psoriasis, sponsored by Celltrion. Started Jan 2021; status: completed.
02
Drugs
ustekinumab CT-P43
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04673786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673786.